Seeking AlphaCodex · 实盘不做把握 5/10
北京时间·🕒 发布 00:58:13时区推断·⟳ 抓取 01:01:00·⚡ 决策 07-25 01:04:04 +3m04s·94.9 天前
FDA顾问委员会对emideltide纳入503A复方原料清单投出负面建议，Hims & Hers盘中大跌
FDA顾问委员会对emideltide出现7票反对、6票支持、1票弃权，削弱Hims & Hers通过多肽复方业务扩张的监管预期。
📄 原文Seeking Alpha↗ 原文
Hims & Hers down as FDA advisors snub first peptide
Shares of Hims & Hers Health (HIMS) dropped more than 11% on Friday after an FDA advisory panel reviewing whether to re…
不做 Hims & Hers Health（HIMS.US）
事件方向偏空，但HIMS已盘中跌11.74%，且Futu行情未给出可借券库存回执，不满足做空红线；负面投票也只是单个多肽且非FDA最终决定，当前不裸开空。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- FDA会议页在7月22日更新材料，确认7月24日审议emideltide、semax和epitalon等503A候选多肽。
- Seeking Alpha报道emideltide投票出现7票反对、6票支持、1票弃权，并称HIMS盘中跌超11%。市场反应:HIMS.US实时报价28.895美元，较前收32.74美元跌11.74%。
- 2026-07-24 13:02 ET市场反应Futu非一手Futu行情显示HIMS.US当日成交额约5.19亿美元、跌11.74%，负面投票已被快速交易。市场反应:盘中已大幅下跌，追空剩余edge降低。
关键理由
- FDA顾问委员会对emideltide出现7票反对、6票支持、1票弃权，削弱Hims & Hers通过多肽复方业务扩张的监管预期。
- FDA官方会议材料确认7月24日审议emideltide、semax和epitalon，503A清单决定虽非最终裁决但直接影响复方药房可用原料范围。
- 量级上，Hims & Hers市值约66.9亿美元，本次只涉及14个候选多肽中的一个且未披露emideltide对应收入，难以量化为足够新的可执行空头收益空间。
主要风险
- 顾问委员会建议不具约束力，且前一日BPC-157等多肽投票被券商解读为对HIMS利好，单个emideltide负票可能被后续正票抵消。
- HIMS已在信号触发附近盘中下跌约11.7%，若无可借券回执，追空容易变成卖在已反应后段。
反向证据
- 做空前查反向 · 来源 kb_search · 日期 2026-07-24 · 影响 weakens
内部KB命中花旗7月23日研报，称PCAC前一日投票结果对HIMS构成明确利好，说明本次负票存在被同一会议其他正票抵消的反证。
检索:HIMS recent bullish counter evidence Novo Wegovy GLP-1 partnership revenue guidance July 2026 原文 ↗ - 做空前查反向 · 来源 stock_quote · 日期 2026-07-24 · 影响 invalidates
Futu full行情未返回enable_short_sell=true和short_available_volume>0的可借券回执，不满足做空执行红线。
检索:HIMS.US full quote borrow availability
历史先例(按相似度)
- 相似度 7/10 HIMS 2026-07-23 PCAC前一日支持BPC-157等多肽纳入503A清单，市场先按HIMS复方多肽机会买入，次日emideltide负票触发反转。 原文 ↗
测HIMS.US在2026-07-23事件日后+1日反应为-11.74%，次日开33.47美元后收28.89美元，明显高开低走。
相似度依据:同一公司、同一PCAC多肽503A机制，但方向相反且只覆盖前一日正票后的次日反应。
工具调用 · 历史记录,结果未知(8 种)
- search_processed_events · 结果未知
- kb_search · 结果未知
- search_case_library · 结果未知
- query_modeling_kb · 结果未知
- normalize_ticker · 结果未知
- price_snapshot · 结果未知
- event_study · 结果未知
- stock_quote · 结果未知
原文全文
展开原文 · 930 字
Shares of Hims & Hers Health (HIMS) dropped more than 11% on Friday after an FDA advisory panel reviewing whether to recommend loosening restrictions on a group of popular peptides indicated its first negative vote.
While six members of the FDA’s pharmacy compounding advisory committee voted in favor of emideltide, a peptide touted for its benefits in opioid withdrawal and chronic insomnia, seven voted against, and one member abstained.
Emideltide was among 14 peptides that the FDA proposed to include on its 503A Bulks List, which compounding pharmacies are allowed to use in the production of customized medications for their clients.
On Thursday, the committee voted in favor of four additional peptides, and the meeting continued on Friday with voting scheduled for emideltide, epitalon, and semax. Hims & Hers (HIMS) is a leading compounding pharmacy operator, having acquired a peptide facility in California last year.
While six members of the FDA’s pharmacy compounding advisory committee voted in favor of emideltide, a peptide touted for its benefits in opioid withdrawal and chronic insomnia, seven voted against, and one member abstained.
Emideltide was among 14 peptides that the FDA proposed to include on its 503A Bulks List, which compounding pharmacies are allowed to use in the production of customized medications for their clients.
On Thursday, the committee voted in favor of four additional peptides, and the meeting continued on Friday with voting scheduled for emideltide, epitalon, and semax. Hims & Hers (HIMS) is a leading compounding pharmacy operator, having acquired a peptide facility in California last year.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。